NRSN - NeuroSense Therapeutics Ltd.

0.9478
-0.022   -2.342%

Share volume: 96,378
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.05%

PREVIOUS CLOSE
CHG
CHG%
$0.97
-0.02
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
8%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 20%
Performance
5 Days
-4.26%
1 Month
-12.43%
3 Months
-8.87%
6 Months
-22.53%
1 Year
-44.90%
2 Year
-44.57%
Key data
Stock price
$0.95
P/E Ratio 
0.00
DAY RANGE
$0.93 - $1.00
EPS 
N/A
52 WEEK RANGE
$0.51 - $1.81
52 WEEK CHANGE
-$42.90
MARKET CAP 
17.329 M
YIELD 
N/A
SHARES OUTSTANDING 
19.471 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
BETA 
1.79
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$135,783
AVERAGE 30 VOLUME 
$174,180
Company detail
CEO: Alon Ben-Noon
Region: US
Website: neurosense-tx.com
Employees: 10
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

NeuroSense Therapeutics Ltd. focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis.

Recent news
loading